Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
Portfolio Pulse from
Achieve Life Sciences reported its financial results for Q4 and year-end 2024, highlighting progress in its cytisinicline development program. The company plans to submit a new drug application (NDA) for cytisinicline by the end of Q2 2025. Key milestones include successful trial enrollments and positive safety reviews.
March 11, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Achieve Life Sciences announced its Q4 and year-end 2024 financial results, emphasizing progress in its cytisinicline program. The company plans to submit an NDA by the end of Q2 2025, with key trial milestones achieved and positive safety reviews.
The announcement of financial results and progress in the cytisinicline program, including the planned NDA submission, is likely to positively impact ACHV's stock. The achievement of key milestones and positive safety reviews further supports this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100